These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37769168)

  • 21. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis.
    Barkas F; Nomikos T; Liberopoulos E; Panagiotakos D
    Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
    Alves AC; Alonso R; Diaz-Diaz JL; Medeiros AM; Jannes CE; Merchan A; Vasques-Cardenas NA; Cuevas A; Chacra AP; Krieger JE; Arroyo R; Arrieta F; Schreier L; Corral P; Bañares VG; Araujo MB; Bustos P; Asenjo S; Stoll M; Dell'Oca N; Reyes M; Ressia A; Campo R; Magaña-Torres MT; Metha R; Aguilar-Salinas CA; Ceballos-Macias JJ; Morales ÁJR; Mata P; Bourbon M; Santos RD
    Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2508-2515. PubMed ID: 32757650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Can We Identify Very High-Risk Heterozygous Familial Hypercholesterolemia?
    Kataoka Y; Funabashi S; Doi T; Harada-Shiba M
    J Atheroscler Thromb; 2022 Jun; 29(6):795-807. PubMed ID: 35022364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia.
    Mizuta MH; Santos RD
    Atherosclerosis; 2022 Oct; 358():57-59. PubMed ID: 36049962
    [No Abstract]   [Full Text] [Related]  

  • 25. Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome.
    Badimon L; Padró T; Cubedo J
    Curr Opin Lipidol; 2017 Oct; 28(5):427-433. PubMed ID: 28682808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detecting Familial hypercholesterolemia in children and adolescents: potential and challenges.
    Banderali G; Capra ME; Biasucci G; Stracquadaino R; Viggiano C; Pederiva C
    Ital J Pediatr; 2022 Jul; 48(1):115. PubMed ID: 35840982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia.
    Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM
    Med Hypotheses; 2018 Dec; 121():60-63. PubMed ID: 30396495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Past, Present, and Future of Familial Hypercholesterolemia Management.
    Rocha VZ; Santos RD
    Methodist Debakey Cardiovasc J; 2021; 17(4):28-35. PubMed ID: 34824679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serious flaws in targeting LDL-C reduction in the management of cardiovascular disease in familial hypercholesterolemia.
    Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM
    Expert Rev Clin Pharmacol; 2021 Mar; 14(3):405-406. PubMed ID: 33565344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
    Pérez de Isla L; Ray KK; Watts GF; Santos RD; Alonso R; Muñiz-Grijalvo O; Diaz-Diaz JL; Badimon L; Catapano AL; Mata P
    Atherosclerosis; 2019 Jul; 286():40-45. PubMed ID: 31100618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
    Gallo A; Pérez de Isla L; Charrière S; Vimont A; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Moulin P; Bruckert E; Mata P; Béliard S;
    JACC Cardiovasc Imaging; 2021 Dec; 14(12):2414-2424. PubMed ID: 34274263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry.
    Alonso R; Díaz-Díaz JL; Arrieta F; Fuentes-Jiménez F; de Andrés R; Saenz P; Ariceta G; Vidal-Pardo JI; Almagro F; Argueso R; Prieto-Matos P; Miramontes JP; Pintó X; Rodriguez-Urrego J; Perez de Isla L; Mata P
    J Clin Lipidol; 2016; 10(4):953-961. PubMed ID: 27578128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?
    Brunham LR
    Curr Opin Lipidol; 2024 Aug; 35(4):219-221. PubMed ID: 38640084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients.
    Pérez de Isla L; Alonso R; Argüeso R; Muñiz-Grijalvo O; Álvarez-Baños P; Badimón L; Watts GF; Mata P;
    J Clin Lipidol; 2022; 16(5):733-736. PubMed ID: 35906178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Two forms of familial hypercholesterolemia: differences in cardiovascular risk factors, cardiac and extracardiac atherosclerosis].
    Vogt A; Keller C; Heigl C; Weiss N; Zöllner N
    Dtsch Med Wochenschr; 2014 Dec; 139(50):2573-7. PubMed ID: 25126774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia.
    Langsted A; Nordestgaard BG
    Curr Atheroscler Rep; 2022 Apr; 24(4):289-296. PubMed ID: 35107760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?
    Brunham LR; Mancini GBJ
    Trends Cardiovasc Med; 2021 May; 31(4):216-217. PubMed ID: 32407995
    [No Abstract]   [Full Text] [Related]  

  • 40. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.